Cytogenetic and molecular characteristics of the cohort of 215 patients with newly diagnosed AML
| Characteristic . | No. of cases . | % . |
|---|---|---|
| Cytogenetic abnormalities | ||
| −9q | 5 | 2.3 |
| −8 | 11 | 5.1 |
| 11q23 | 6 | 2.8 |
| −5/−5(q)/−7/−7(q) | 16 | 7.4 |
| Complex | 5 | 2.3 |
| Inv(16) | 15 | 7.0 |
| Normal karyotype (NK) | 100 | 46.5 |
| t(15;17) | 6 | 2.8 |
| t(6;9) | 2 | 0.9 |
| t(8;21) | 12 | 5.6 |
| t(9;22) | 2 | 0.9 |
| −X/Y | 3 | 1.4 |
| Other | 30 | 14.0 |
| Not determined | 2 | 0.9 |
| Total | 215 | 100.0 |
| Molecular abnormalities | ||
| FLT3-TKD | 20 | 9.3 |
| FLT3-ITD | 62 | 28.8 |
| N-RAS | 22 | 10.2 |
| K-RAS | 1 | 0.5 |
| CEBPA | 22 | 10.2 |
| NPM1 | 68 | 31.6 |
| Total patients | 215 | 100.0 |
| Normal karyotype | 100 | 100.0 |
| With FLT3-TKD | 10 | 10.0 |
| With FLT3-ITD | 45 | 45.0 |
| With N-RAS | 11 | 11.0 |
| With K-RAS | 0 | 0.0 |
| With CEBPA | 19 | 19.0 |
| With NPM1 | 55 | 55.0 |
| Characteristic . | No. of cases . | % . |
|---|---|---|
| Cytogenetic abnormalities | ||
| −9q | 5 | 2.3 |
| −8 | 11 | 5.1 |
| 11q23 | 6 | 2.8 |
| −5/−5(q)/−7/−7(q) | 16 | 7.4 |
| Complex | 5 | 2.3 |
| Inv(16) | 15 | 7.0 |
| Normal karyotype (NK) | 100 | 46.5 |
| t(15;17) | 6 | 2.8 |
| t(6;9) | 2 | 0.9 |
| t(8;21) | 12 | 5.6 |
| t(9;22) | 2 | 0.9 |
| −X/Y | 3 | 1.4 |
| Other | 30 | 14.0 |
| Not determined | 2 | 0.9 |
| Total | 215 | 100.0 |
| Molecular abnormalities | ||
| FLT3-TKD | 20 | 9.3 |
| FLT3-ITD | 62 | 28.8 |
| N-RAS | 22 | 10.2 |
| K-RAS | 1 | 0.5 |
| CEBPA | 22 | 10.2 |
| NPM1 | 68 | 31.6 |
| Total patients | 215 | 100.0 |
| Normal karyotype | 100 | 100.0 |
| With FLT3-TKD | 10 | 10.0 |
| With FLT3-ITD | 45 | 45.0 |
| With N-RAS | 11 | 11.0 |
| With K-RAS | 0 | 0.0 |
| With CEBPA | 19 | 19.0 |
| With NPM1 | 55 | 55.0 |